Related Experiment Video
Updated: Aug 7, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Giant cell arteritis complicated by aortic aneurysmal disease
1Amerus Life Insurance Group, 9200 Keystone Crossing, Suite 800, Indianapolis, IN 46240-4603, USA. jack.cotlar@indianapolislife.com
Insights
Giant cell arteritis (GCA) patients have similar mortality rates to the general population. Excess deaths may stem from aortic aneurysms, necessitating vigilant physician assessment and insurer awareness.
Area of Science:
- Cardiovascular Medicine
- Rheumatology
- Medical Insurance
Background:
- Giant cell arteritis (GCA) is a systemic vasculitis primarily affecting large arteries.
- While GCA treatment can be effective, long-term complications require ongoing monitoring.
- Aortic aneurysms, particularly thoracic aortic dissection, are identified as potential serious complications of GCA.
Purpose of the Study:
- To evaluate the mortality rates in patients diagnosed with giant cell arteritis (GCA).
- To identify potential causes of excess mortality in GCA patients beyond the disease's direct inflammatory effects.
- To highlight the importance of recognizing and managing aortic aneurysm risk in GCA survivors and inform insurance underwriting processes.
Main Methods:
- Comparative analysis of mortality rates between GCA patients and age/sex-matched general populations.
- Review of potential causes for excess mortality, focusing on cardiovascular complications.
- Assessment of information transfer between treating physicians and insurer underwriting departments regarding patient risk factors.
Main Results:
- Overall mortality in GCA patients is comparable to standard populations.
- Excess mortality, when present, is often linked to aortic aneurysms, including thoracic aortic dissection.
- Aneurysms can manifest years after GCA treatment cessation, underscoring the need for long-term surveillance.
Conclusions:
- Physicians must remain vigilant for thoracic and abdominal aortic aneurysms in GCA patients, even after treatment completion.
- Medical records submitted to insurers may lack critical details, necessitating proactive information retrieval by underwriting departments.
- Insurers need strategies to address potential data omissions and ensure accurate risk assessment for GCA patients.
Abstract:
The mortality rate in patients with giant cell arteritis (GCA) is similar to the standard populations of similar age and sex. Where there is excess mortality, it may be due to aortic aneurysms, especially thoracic aortic dissection as complications of GCA disease. Aneurysms may develop years after cessation of treatment. The treating physician should be vigilant in assessing the patient with giant cell arteritis for thoracic and abdominal aortic aneurysms. However, the physician's medical records that are sent to the insurer's underwriting department may omit key information such as recommended studies. The underwriting department should have a strategy to quickly resolve this problem.
Related Concept Videos
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Aneurysm III: Interprofessional Care
Aneurysm I: Introduction
Aortic Regurgitation I: Introduction
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Rheumatic Heart Disease I: Introduction

